Drug intelligence / Profile preview

CUG115

Development stage: Preclinical
Lead developer: Cugene
Modality: Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

CUG115 is an investigational drug developed by Cugene. It is classified as an interleukin-15 (IL-15) replacement and functions as a T lymphocyte stimulant. The drug is designed to mimic or replace the activity of IL-15, a cytokine involved in the activation and proliferation of T cells, which play a critical role in immune responses. Its primary therapeutic area is oncology, specifically for the treatment of solid tumors. As of April 2025, its highest development status globally is preclinical[1].

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on CUG115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUG115.

Explore the full profile